Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants

NCT ID: NCT02123927

Last Updated: 2014-04-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 108 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-09-30
• Study Completion Date: 2007-12-31

Brief Summary

The primary purpose of this study was to evaluate the single dose safety and pharmacokinetics of TAK-438 in healthy Japanese men.

Detailed Description

The drug being tested in this study is called TAK-438. TAK-438 is being tested to find a safe and well-tolerated dose and to assess how TAK-438 moves throughout the body. This study will look at lab results and side effects in people who took TAK-438. This study consisted of 2 sequential studies: a single rising dose study (Steps 1 to 7) and a food-effect study (Steps 8 and 9).

The study population for Steps 1 to 7 consisted of 12 participants; with 9 participants randomized to receive a single dose of TAK-438, and 3 participants to receive placebo. Participants in Steps 1 to 7 received a single dose of study drug after a 10-hour fast. The starting dose was 1 mg followed by administrations of 5, 10, 20, 40, 80, and 120 mg. Steps 8 and 9 consisted of 12 participants in a 2-sequence, 2-period crossover design. Four participants were to receive a single dose of TAK-438 and 2 participants were to receive a single dose of placebo on Day 1, in the fasted state, and 4 participants were to receive a single dose of TAK-438 and 2 participants were to receive a single dose of placebo on Day 1 in the fed state, followed by a second single dose of TAK-438 or placebo in the alternative fed state after a 13 day minimum washout period. Participants in Steps 8 randomized to receive TAK-438 will receive 10 mg and participants in Step 9 will receive 40 mg.

This single-centre trial was conducted in Japan. The overall time to participate in this study was up to 32 days depending on the Step assignment. Participants made 3 to 5 visits to the clinic, including one or two 8-day periods of confinement to the clinic, also depending on Step assignment. All participants made a final visit 15 days after last dose of study drug for a follow-up assessment.

Conditions

Ascending Single Dose Study

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Step 1: TAK-438 1 mg

TAK-438 1 mg, tablets, orally, once on Day 1.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Step 2: TAK-438 5 mg

TAK-438 5 mg, tablets, orally, once on Day 1.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Step 3: TAK-438 10 mg

TAK-438 10 mg, tablets, orally, once on Day 1.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Step 4: TAK-438 20 mg

TAK-438 20 mg, tablets, orally, once on Day 1.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Step 5: TAK-438 40 mg

TAK-438 40 mg, tablets, orally, once on Day 1.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Step 6: TAK-438 80 mg

TAK-438 80 mg, tablets, orally, once on Day 1.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Step 7: TAK-438 120 mg

TAK-438 120 mg, tablets, orally, once on Day 1.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Steps 1-7: Placebo

TAK-438 placebo-matching tablets, orally, once on Day 1.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

TAK-438 placebo-matching tablets

Step 8A: TAK-438 10 mg

TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Step 8 B: TAK-438 10 mg

TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Step 9A: TAK-438 40 mg

TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Step 9B: TAK-438 40 mg

TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.

Group Type: EXPERIMENTAL

TAK-438

Intervention Type: DRUG

TAK-438 tablets

Steps 8 (A & B) and 9 (A & B): Placebo

TAK-438 placebo-matching tablets, orally, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 placebo-matching tablets, orally, once on Day 1, Period 2.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

TAK-438 placebo-matching tablets

Interventions

TAK-438

TAK-438 tablets

Intervention Type: DRUG

Placebo

TAK-438 placebo-matching tablets

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Japanese healthy adult male volunteer.

2. Is between 20 and 45 years old when giving their informed consent.

3. Is able to understand the consents of the study and to follow them.

4. Provides their written informed consent prior to their participation in this study.

5. Weighs at least 50 kg and has a body mass index (BMI) of 18.5 to 25.0 kg/m^2 at screening.

6. Has negative results for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, and serological tests for syphilis.

7. Participant whom the investigator or subinvestigator judged to be eligible on the basis of subjective symptoms, objective findings, vital signs, electrocardiogram (ECG) findings, and results of laboratory tests obtained until before the study drug administration.

Exclusion Criteria

1. Has undergone upper gastrointestinal resectioning or vagotomy.

2. Has hypoacidity or anacidity: intragastric pH ≥ 5.5 at X-ray fluoroscopic confirmation of detained position of a pH probe inserted to measure baseline intragastric pH values.

3. Has a history of previous and current acid-related diseases including reflux esophagitis, gastric ulcer, duodenal ulcer, non-erosive gastroesophageal reflux disease, Barrett's esophagitis or Zollinger-Ellison syndrome.

4. Is undergoing H. pylori eradication within 6 months before the initiation of the study drug administration.

5. Has an inappropriate history of previous and current diseases for study participation including hepatic or renal disorders, and cardiovascular, hematological, endocrine, metabolic, pulmonary, gastrointestinal, neurological, urological, immunological, or psychological diseases.

6. Has a history of drug and food allergy.

7. Has a history of illegal drug abuse or alcoholism within 5 years before the initiation of the study drug administration.

8. Has peripheral vessels being difficult.

9. Has undergone whole blood drawing of at least 200 mL within 4 weeks or 400 mL within 12 weeks prior to initiation of the study drug administration.

10. Has undergone whole blood drawing of at least 800 mL in total within 52 weeks prior to initiation of the study drug administration.

11. Has undergone apheresis drawing [plasma (including platelet poor plasma or platelet rich plasma) and platelet component collection] within 2 weeks prior to initiation of the study drug administration.

12. Is taking any prescriptions or over the counter (OTC) drugs within 4 weeks prior to the study drug administration.

13. Has taken any vitamins, herbal medicines, and supplements including St. John's wort, Ginseng, kava kava, ginkgo biloba, melatonin within 4 weeks prior to initiation of the study drug administration.

14. Has had grapefruit (juice and pulp), or caffeine- or alcohol-containing foods or drinks within 72 hr prior to initiation of the study drug administration.

15. Has received other study drugs within 16 weeks prior to initiation of the study drug administration.

16. Participants whom the investigator or subinvestigator judged to be ineligible for study participation.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director Clinical Science

Role: STUDY_DIRECTOR

Takeda

Other Identifiers

U1111-1153-7002

Identifier Type: OTHER

Identifier Source: secondary_id

TAK-438/CPH-001

Identifier Type: -

Identifier Source: org_study_id